Ferrante K L, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, Fantasia M, Taft J, Beal M F, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, Cudkowicz M
Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Neurology. 2005 Dec 13;65(11):1834-6. doi: 10.1212/01.wnl.0000187070.35365.d7.
An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.
进行了一项开放标签剂量递增试验，以评估高剂量辅酶Q10（CoQ10）在肌萎缩侧索硬化症（ALS）中的安全性和耐受性。CoQ10是线粒体电子传递中的一种辅助因子，可能改善ALS中的线粒体功能障碍。在本研究中，31名受试者接受高达3000毫克/天的剂量治疗8个月，CoQ10是安全的且耐受性良好。
